CD47 and neoplasm: Several studies have attempted to improve the tumor selectivity of anti-CD47 agents by generating bispecific antibodies (i.e., an antibody which recognizes two different antigens on tumor cells simultaneously), which have been demonstrated to minimize side effects [34, 51].